MicroRNAs (miRNAs) are a class of 20-24 nt noncoding RNAs that regulate target mRNAs posttranscriptionally by binding with imperfect complementarity in the 3 0 -untranslated region (3 0 -UTR) and inhibiting translation or RNA stability. Current understanding of miRNA biology is limited, and antisense oligonucleotide (ASO) inhibition is a powerful technique for miRNA functionalization in vitro and in vivo, and for therapeutic targeting of miRNAs. Identification of optimal ASO chemistries for targeting miRNAs is therefore of great interest. We evaluated a number of 2 0 -sugar and backbone ASO modifications for their ability to inhibit miR-21 activity on a luciferase reporter mRNA. ASO modifications that improved target affinity improved miRNA ASO activity, yet the positioning of highaffinity modifications also had dramatically different effects on miRNA activity, suggesting that more than affinity determined the effectiveness of the miRNA ASOs. We present data in which the activity of a modified miRNA ASO was inversely correlated to its tolerability as an siRNA passenger strand, suggesting that a similar mechanism could be involved in the dissociation of miRNA ASOs and siRNA passenger strands. These studies begin to define the factors important for designing improved miRNA ASOs, enabling more effective miRNA functionalization and therapeutic targeting.
INTRODUCTION
MicroRNAs (miRNAs) are a class of endogenously expressed small regulatory noncoding RNAs thought to negatively regulate target mRNAs by binding with imperfect complementarity in their 3 0 -untranslated regions (3 0 -UTRs) (1) (2) (3) (4) . Based on early studies in invertebrates, miRNAs are expected to have roles in developmental regulation and cell differentiation in mammals, and roles for miRNAs in cardiogenesis (5) and lymphocyte development (6) have been demonstrated. Several studies suggest a strong connection between miRNA and human cancer (7) (8) (9) (10) (11) (12) . Recent reports implicate roles for mammalian miRNAs in metabolic pathways (13) (14) (15) (16) . MiRNAs have also been shown to suppress (17) and enhance (18) levels of viral RNA in cells. Despite this growing list of roles for mammalian miRNAs, most of the hundreds of miRNAs identified in mammals (19, 20) have no reported function.
Conventional single strand antisense oligonucleotides (ASOs) (13, (21) (22) (23) (24) (25) or double strand siRNAs (26) (27) (28) (29) (30) targeting coding genes have been successfully used to screen for gene function in high-throughput cellular assays. ASOs have also been widely used to evaluate gene function and validate gene targets in vivo (31) (32) (33) (34) (35) (36) (37) and several antisense therapeutics are in clinical trials (35, (38) (39) (40) (41) (42) (43) . For many cellular applications and all in vivo studies, chemically modified oligonucleotides were used. Properties of modified oligonucleotides associated with improved activity include improved hybridization affinity for the target nucleic acid, resistance to endogenous nucleases, or improved activation of RNase H or other proteins involved in the terminating mechanism. In addition, alteration of protein binding properties with the aim of improving ASO delivery or altering toxicological profiles can be beneficial (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . Recently, anti-miRNA ASOs have been used to examine functions of miRNAs in flies (57) (58) (59) , mammalian cells (13, 14, (60) (61) (62) (63) and mice (15, 16) . Therapeutic potential for anti-miRNA ASOs has even been suggested (14) (15) (16) 18, 64) . In contrast to the extensive optimization of oligonucleotide chemistry for ASOs targeting mRNA or pre-mRNA, little has been done to optimize the chemistry for ASOs targeting miRNAs. Most of the studies mentioned above employed 2 0 -O-methyl (2 0 -O-Me) substituted RNA oligonucleotides. There are also reports using DNA (57, 59) or a mixed locked nucleic acid (LNA)-DNA ASO (62) and two studies have used 2 0 -O-methoxyethyl (2 0 -O-MOE) substituted RNA oligonucleotides (13, 16) . We set out to evaluate the effect of ASO structure and modification on antimiRNA activity, using a 'luciferase sensor' assay for miR-21 activity in Hela cells. We report below effects of 2 0 -sugar and backbone modification on activity of anti-miRNA ASOs. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
MATERIALS AND METHODS

Oligonucleotide synthesis
Oligonucleotides were prepared using conventional phosphoramidite chemistry and DNA synthesis equipment (Applied Biosystems). The 2 0 modified phosphoramidites and succinatelinked solid support were obtained from commercial sources. The purity of all samples was >85% as monitored by electrospray ionization-mass spectrometry analysis. miR-21 ASO sequence: 5 0 -TCAACATCAGTCTGATAAGCTA-3 0 . For all modified ASOs except the 2 0 F, C was methylated at the 5 position. The 2 0 F ASO had unmethylated C and uracil replaced thymine.
siRNA preparation
Oligonucleotides for preparation of siRNA duplexes were ordered from Dharmacon or Integrated DNA Technologies. Oligonucleotides were purified using high-performance liquid chromatography (HPLC). Strands to be annealed were mixed at equal concentrations in 5· annealing buffer (Dharmacon) and incubated at 90 C for 2 min. The mixture was gradually cooled on a 37
C heat block to allow duplexes to form. The sequence of the siRNA targeting human PTEN: 5 0 -UUUGU-CUCUGGUCCUUACUUCC-3 0 (guide, unmodified RNA); 5 0 -GGAAGTAAGGACCAGAGACAAA-3 0 (passenger, various chemistries as described in Results).
Luciferase sensor assay
The miR-21 luciferase sensor construct was engineered by inserting the full 22 bp sequence complementary to the mature miR-21 into the 3 0 -UTR of pGL3-Control (Promega). Hela cells were propagated in DMEM with High Glucose (Gibco) supplemented with 10% FBS (Gibco). 3.5 · 10 6 Hela cells in T-170 flasks (BD Falcon) were transfected in batch with 10 mg miR-21 luciferase sensor plasmid and 0.5 mg of phRL-CMV plasmid (Promega) for normalization using 20 ml/flask Lipofectamine 2000 (Invitrogen). After 4 h of transfection, cells were washed, trypsinized, and re-plated at 40 000 cells/well in 24-well plates (BD Falcon). The following day, cells were transfected in triplicate with ASOs for 4 h using Lipofectin (Invitrogen) at 2.5 ml Lipofectin/100 nM ASO/ml Opti-MEM I (Gibco). After ASO transfection, Hela cells were re-fed with complete media. Cells were lysed 24 h later, unless otherwise indicated, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Each experiment was performed at least three times and a representative example is shown. Control ASOs of matched chemistry but unrelated sequence were evaluated in each experiment and, in general, did not affect luciferase activity significantly compared to mock transfected control cells.
Cell proliferation assay
Hela cells were plated at 4000 cells/well in 96-well plates (BD Falcon). The following day, cells were transfected in triplicate with ASOs for 4 h using Lipofectin (Invitrogen) at 2.5 ml Lipofectin/100 nM ASO/ml Opti-MEM I (Gibco). After ASO transfection, Hela cells were re-fed with DMEM with high glucose and without phenol red (Gibco) supplemented with 10% FBS (Gibco). After 24 h, the cell viability was investigated using CellTiter 96Ò AQ ueous One Solution Cell Proliferation Assay (Promega).
siRNA transfection
Hela cells were plated in 96-well plates (BD Falcon) at 4000 cells/well overnight. The following day, cells were treated with duplexes at various concentrations with 5 ml Lipofectamine 2000 (Invitrogen)/ml Opti-MEM I (Gibco) for 4 h. After the 4 h treatment, the Hela cells were re-fed with complete media and left overnight. The next day, cells were lysed and total RNA was isolated using RNeasy 96 columns (Qiagen) on a BioRobot 3000 (Qiagen). Levels of human PTEN mRNA were assayed using real-time Taqman 
T m measurements
Absorbance versus temperature curves were measured at 260 nm using a Gilford Response II spectrophotometer. The buffer contained 100 mM Na + , 10 mM phosphate and 0.01 mM EDTA (pH 7.0) with sufficient Cl À to achieve ionic neutrality. Oligonucleotide concentration was 4 mM each strand determined from the absorbance at 85 C and extinction coefficients calculated according to Puglisi and Tinoco (65) . T m 's of duplex formation were obtained from fits of data to a two state model with linear sloping baselines (66) .
RESULTS
Selection of a sensitive assay for anti-miRNA activity
MiRNAs regulate their targets post-transcriptionally, either by inhibiting translation or causing mRNA degradation. Directly confirmed, translationally-regulated targets are few (67) (68) (69) , and western blotting assays are cumbersome for rapid screening of anti-miRNA ASO activity. Changes in target mRNA levels after miRNA modulation have been reported (15, 16, 70) , but the magnitude of the reported changes is small, often only 2-to 3-fold. We attempted to identify a miR-21 target gene upregulated in Hela cells at the mRNA level after ASO treatment. Taqman RT-PCR following ASO treatment was used to measure levels of 26 mRNAs predicted by the TargetScan algorithm (71) to be targets of miR-21. Two mRNAs were identified that appeared to be upregulated after miR-21 ASO treatment (data not shown), but each mRNA was increased no more than 2-fold, making it difficult to compare subtle differences in activity among modified ASOs.
For comparison of modified miRNA ASOs, we needed a convenient and sensitive system with a good dynamic range for evaluation of miRNA activity. Incorporation of perfectly complementary miRNA binding sites into the 3 0 -UTR of a reporter plasmid has been used previously to evaluate endogenous miRNA activity (72) (73) (74) (75) . We created a miR-21 luciferase 'sensor' plasmid for use in these studies, as miR-21 is abundant in Hela cells. When transfected into Hela cells, the endogenously-expressed miR-21 strongly represses the luciferase sensor expression (data not shown), presumably by binding with perfect complementarity and causing cleavage of the mRNA. Introduction of a miR-21 ASO can prevent this inhibition, resulting in increased luciferase expression. Using this system, the effect of various modified ASOs targeting the mature miR-21 sequence could be easily compared.
Effect of 2
0 -sugar substitution on anti-miRNA activity
We first evaluated effects of several 2 0 -sugar modifications on miRNA ASO activity 24 h after ASO transfection. Phosphorothioate (PS) oligonucleotides with uniform 2 0 -O-MOE, 2 0 -O-Me or 2 0 -flouro (2 0 F) substitution were tested along with a 2 0 -O-MOE-PS compound containing seven high affinity LNA substitutions, one at every third position. The T m 's for these ASOs hybridized to a length matched complementary RNA were measured and are shown in Table 1 . As predicted (50, 56, 76) , all 2 0 substitutions increased affinity significantly compared to DNA with 2
, and these high affinity ASOs were all more active than the 2 0 -deoxy-PS oligonucleotide which was inactive in this assay (data not shown).
Anti-miRNA ASOs modified with LNA are also commercially available from Exiqon. The miRCURY miRNA knockdown probe targeting miR-21 was evaluated in the luciferase sensor assay and compared to the 2 0 -O-MOE-PS ASO ( Figure 1B ). The 2 0 -O-MOE ASO showed better activity at the higher doses, although the compounds were similar at the lowest dose.
We noticed that some modified ASOs, primarily 2 0 -OMe-PS and 2 0 -F-PS, had negative effects on cell growth during the luciferase assay. In order to quantify the potential cytotoxic effects of the ASOs, a cell proliferation assay was performed 24 h after ASO treatment ( Figure 1C ). After treatment with 100 nM ASO, significant inhibition in cell proliferation was observed after treatment with the 2 0 -O-Me-PS and the 2 0 -F-PS ASOs. A minor inhibition was observed after treatment with the 2 0 -O-MOE-PS ASO. Similar effects were observed after treatment with control ASOs of unrelated sequence but with the same sugar and backbone modifications (data not shown), ruling out the possibility that the proliferation defect was related to miR-21 inhibition. After 33 nM ASO treatment, only minor effects on cell proliferation were observed for the 2 0 -O-Me and 2 0 -F modified ASOs. At 11 nM ASO treatment, no significant effects on cell proliferation were observed.
Effect of phosphodiester backbone on anti-miRNA activity 2 0 -O-MOE and 2 0 -O-Me ASOs with unmodified phosphate (PO) backbones were also evaluated. The PS modification is estimated to cause a 0.5-0. 7 C decrease in T m for each modification (50, 76, 77) , so keeping the nucleosidic linkages as a phosphodiester was expected to result in improved target affinity. For these two ASOs, the T m increase was only 4.4 C for the 2 0 -O-Me modified ASO, and 7.3 C for the 2 0 -O-MOE ASO. This increased T m resulted in improved activity for the 2 0 -O-MOE-PO ASO, compared to the 2 0 -O-MOE-PS ASO. However, changing the backbone of the 2 0 -O-Me ASO from PS to PO gave no increase in activity. A 2 0 F phosphate backbone ASO was not tested, as it is expected to be susceptible to nuclease degradation within a short time (78) and a DNA-PO ASO had no activity (data not shown). 0 -deoxy nucleotides in the center, is capable of triggering RNase H-dependent degradation of an RNA target. However, it was not effective at inhibiting miR-21 activity (Figure 3, Compound 9 ), suggesting that the miRNA-ASO complex may not be accessible to the RNase H enzyme. Apparently this gapmer ASO was also unable to work effectively using the non-RNase H mechanism(s) employed by the uniformly 2 0 substituted ASOs. Substitution of a 2 0 -O-MOE residue with DNA in an ASO-RNA duplex reduces the T m by 1-2 C per substitution (50, 76, 79) . We therefore hypothesized that inactivity of the 2 0 -O-MOE gapmer-PS ASO was due to a decrease in target RNA binding affinity compared to the uniform 2 0 -O-MOE PS. To test this hypothesis, a series of ASOs was designed by varying positioning of the 2 0 -O-MOEs (Figure 3 ), and effects on T m and miR-21 activity were evaluated. Like the original 5-10-7 gapmer, each ASO had twelve 2 0 -O-MOE and ten 2 0 -deoxy residues. Measured T m 's for the mixed DNA-MOE compounds were all between that of the full DNA and the uniform 2 0 -O-MOE compounds (Table 1) . We were surprised to discover that compounds with the same number of 2 0 -O-MOE and deoxy residues could have dramatically different effects on anti-miRNA activity (Figure 3 ). For some compounds, the differences in activity correlated with the observed T m . For example, inverting the 2 0 -O-MOE gapmer-PS design so that twelve 2 0 -O-MOE modifications were flanked by five 2 0 -deoxy residues on either side (Figure 3 Comparison of anti-miRNA activity to siRNA activity These data suggested that while affinity for target RNA is important for effective miRNA inhibition, other factors may also contribute. An anti-miRNA ASO binding to mature miRNA in RISC could be thought of as a passenger strand of the miRNA or an siRNA. There is now evidence that the double-stranded si/miRNA may associate with the Argonaute protein in RISC before passenger strand dissociation (81-85), and it is therefore possible that the activity responsible for the unwinding of the passenger strand is still associated with the complex when the anti-miRNA ASO binds. In this case, the same interactions influencing the tolerability of chemical modification of siRNA passenger strands may also hold true for modified anti-miRNA ASOs. Using a model siRNA targeting the PTEN mRNA, a set of modified sense, or passenger strands were paired with an unmodified RNA antisense, or guide strand, and tested for their ability to reduce PTEN mRNA levels in Hela cells (Figure 4) . The best antimiRNA ASO tested, the uniformly modified MOE-PO ( Figure 4 but with some loss of activity compared to unmodified RNA (Figure 4, Compound 14) . Surprisingly, the MOE-DNA-MOE gapmer (Figure 4, Compound 20) , and the alternating MOE-DNA motif (Figure 4 , Compound 21) were both tolerated as siRNA passenger strands, with no loss of activity compared to unmodified RNA. These motifs were both ineffective as anti-miRNA ASOs. In general, anti-miR-21 activity for each modified passenger strand/miRNA ASO was inversely correlated with PTEN siRNA activity ( Table 2) .
Mismatch specificity and length requirements for anti-miRNA ASOs
Finally, we examined the specificity and length requirements of the uniformly-modified 2 0 -O-MOE-PS ASOs. Many miRNAs come in families that share a 6-8 nt 'seed' sequence at the 5 0 part of the miRNA, and some differ by only one or two nucleotides. As family members are predicted to regulate overlapping sets of target genes, it may be advantageous to be able to target multiple family members with a single ASO. Alternatively, there may be situations in which targeting a single family member is desired. Measuring levels and activities of multiple related miRNAs is technically challenging, but we can infer from the specificity of ASOs mismatched to miR-21 the likelihood of targeting multiple family members with a single ASO. A total of 1 to 6 nt mismatches were introduced into 2 0 -O-MOE-PS ASOs at a number of positions, and anti-miR-21 activity was measured 24 h after treatment ( Figure 5A ). Three of four ASOs evaluated with a single mismatch substantially reduced, but did not ablate, anti-miR-21 activity. The introduction of a single mismatch into the 3 0 end of the ASO, which is complementary to the 5 0 seed region of the miRNA, resulted in an additional loss of activity relative to the other ASOs containing a single mismatch. ASOs with two or more mismatches to miR-21 had poor activity, and three or more mismatches resulted in a complete loss of activity. These data suggest that anti-miRNA ASOs are likely to be specific for individual miRNA family members.
We also tested the effect of truncation on the ASOs' antimiRNA activity. 2 0 -O-MOE-PS ASOs with one to five truncated nucleotides from either the 5 0 or 3 0 end were evaluated for their ability to inhibit miR-21 activity ( Figure 5B) . A 1 nt truncation from either end of the ASO was well tolerated with little loss of activity. Interestingly, truncating a single nucleotide from the 3 0 end of the ASO modestly improved activity. In this case, the truncated nucleotide would be complementary to the first nucleotide of the miRNA, which is supposed to be tucked into a pocket of the Piwi domain of the Argonaute protein in RISC and not available to interact with target RNA (86, 87) . Truncating 2 nucleotides from either end of the ASO resulted in a loss of activity, although again a truncation from the 3 0 end was better tolerated than a truncation from the 5 0 end. Three or more truncations from either end resulted in a substantial loss of anti-miRNA activity.
Effect of inhibition of miRNA activity on miRNA levels
Degradation of the mature miRNA has been reported after in vivo inhibition of miR-122 with uniformly 2 0 -substituted ASOs (15, 16) . To test if the same effect was observed in vitro, we examined the effect of ASO inhibition on miR-21 levels in Hela cells after ASO treatment (Figure 6 ). There was a dosedependent decrease in the levels of miR-21 detected on a northern blot 24 h after treatment with the 2 0 -O-MOE-PS ASO targeting miR-21, but not with a control ASO, indicating that degradation of the mature miRNA also occurred in vitro and on a similar time frame as the changes in luciferase sensor activity that we observed.
DISCUSSION
In this study we set out to identify the optimal modified chemistries for inhibition of miRNA activity by ASOs. Few miRNAs have been assigned any function, and antisense oligos are a convenient method for inhibiting them. Antisense targeting may be the only possible approach for therapeutically inhibiting miRNAs, since the active molecule is a small RNA, which will be challenging to target specifically without using Watson-Crick base pairing. Therefore, identifying optimal chemistries for miRNA inhibition is crucial for effective functionalization and therapeutic targeting of miRNAs.
The ASOs evaluated in this study are complementary to mature miR-21, but could interfere with miRNA processing by binding to pri-or pre-miRNA. They could also act after Dicer processing, but before loading of the mature miRNA into Argonaute. At least one study suggested that ASOs targeting miRNA act primarily by binding to the mature miRNA and blocking its function in RISC (59). Krutzfeldt et al. (15) reported in vivo reduction of mature miR-122 with no effect on pre-miR-122 levels, also pointing to the mature miRNA as the primary site of action of the ASO. Two observations in this study are consistent with this model. First, inhibition of miRNA activity and reduction of mature miRNA levels occurred within 24 h. There is evidence to suggest that RISC-loaded mature miRNA is long-lived, as inhibition of Drosha processing, pre-miRNA nuclear export, or the PACT protein shown to be involved in RISC loading, had minimal effects on the steady-state levels of mature miRNAs (88) (89) (90) (91) . If the ASO were inhibiting miRNA processing or loading, effects on miRNA activity would not be observed until turnover of the RISC-loaded mature miRNA. Second, the correlation in Table 2 between active miRNA ASOs and poor siRNA passenger strands implies that the ASO is acting at the site of passenger strand unwinding, which has been reported to be in RISC (81) (82) (83) (84) (85) . Thus, while we cannot rule out the possibility that the ASO inhibits miRNA processing or RISC loading, our data and others so far suggest the ASO acts primarily on mature miRNA in RISC.
The initial set of modified ASOs was designed to evaluate the role of affinity in anti-miRNA ASO activity. In the context of a PS modified backbone, the degree of miRNA inhibition correlated loosely with affinity. The two modifications with the highest T m 's, uniform 2 0 -F and the 2 0 -LNA/MOE mixed sugar, were most active. That discrepancy, and the difference in activity between the 2 0 -O-MOE/2 0 -deoxy hemimer ASOs in spite of their almost identical T m 's, suggested that in some cases, more than affinity determined effective miRNA inhibition. This led us to the speculation that an anti-miRNA ASO, if it is acting primarily on mature miRNA in RISC, is analogous to a passenger strand of an siRNA or miRNA. Perhaps the same rules governing tolerability of chemical modification of siRNA passenger strands also hold true for modified anti-miRNA ASOs. Indeed, this is what we found. There was, generally speaking, an inverse correlation of PTEN siRNA activity with antimiR-21 activity for each modified passenger strand/miRNA ASO. The best anti-miRNA ASO tested, the uniformly modified 2 0 -O-MOE-PO, was completely inactive as a PTEN siRNA passenger strand. The least active anti-miRNA ASOs, the MOE-DNA-MOE gapmer, and the alternating MOE-DNA motif, were the most active siRNA passenger strands. These data support the hypothesis that a similar mechanism could be involved in dissociation of an siRNA passenger strand and dissociation of an anti-miRNA ASO, which would result in ineffective inhibition of miRNA activity. It remains to be seen whether this hypothesis will be useful for predicting additional designs for active anti-miRNA ASOs.
Theoretically, the 2 0 -O-MOE gapmer ASO targeting the mature miRNA sequence could inhibit miRNA activity via an RNase H-based mechanism, acting on the mature, preor pri-miRNA. However, we observed little anti-miRNA activity in the luciferase sensor assay with the 2 0 -O-MOE gapmer. It is likely that the mature miRNA in RISC is not accessible to the RNase H enzyme. The possibility that the 2 0 -O-MOE gapmer ASO could target the pri-or pre-miRNA is still open, since this would inhibit production of new mature miRNA. Any measurable effects would depend on the rate of turnover of the already present mature miRNA, which may not be observable in the time-frame of these assays, as the half-life of mature miRNA is thought to be long (88) (89) (90) (91) . In addition, the mature miRNA is found in a structured hairpin in the priand pre-miRNA, and structured hairpin targets tend to reduce ASO activity (92) . Targeting the pri-miRNA transcript outside the hairpin structure may be a better strategy for ASOs using an RNase H mechanism. Targeting the pri-miRNA transcript with siRNA is not likely to be an option, since pri-miRNA transcripts are found primarily in the nucleus, and siRNA targeting of pre-miRNAs has been reported to be inefficient, requiring much higher doses of siRNA than usually needed for targeting mRNAs (60) . RNase H ASOs, on the other hand, have successfully been used to target noncoding RNAs in the nucleus (93) .
These studies outline some of the factors important for effective targeting of miRNA with ASOs in cell culture. We evaluated effects of 2 0 -sugar and backbone ASO modifications, and their placement within the ASO. While affinity for the target miRNA was the most important determinant of anti-miRNA activity, our results suggested that to be an effective miRNA ASO, it may also be necessary to avoid dissociation by the factors responsible for si/miRNA passenger strand unwinding. Mismatches were not well tolerated, suggesting it will be difficult to target multiple miRNA family members with a single ASO. Truncation studies indicated that although significant activity was retained with truncation of just 1 nt, loss of two or more nucleotides resulted in a substantial loss of anti-miRNA activity.
These studies focused on a single miRNA in a single assay system. It will be essential to extend these studies to target other miRNAs, with other assays for miRNA activity. As several natural targets for miRNAs have now been identified, it will be possible to perform studies that measure ASO effects on miRNA target protein or mRNA levels directly. In addition, other factors will have to be considered in optimizing in vivo anti-miRNA activity for therapeutic targeting, as the pharmacokinetic properties of an ASO can dramatically influence its effectiveness in an animal. Data from in vivo targeting of miR-122 suggested that the outcome of miRNA ASO inhibition is degradation of the mature miRNA (15, 16) , and we also observed reduction in miR-21 levels after inhibition with a 2 0 -O-MOE-PS ASO in these studies. It's not clear how ASO binding to a miRNA in RISC results in disappearance of the mature miRNA, but understanding the mechanism of degradation may lead to more effective methods of miRNA targeting, and it will be an important question for future studies.
